North American Scientific Receives Notice of Non-Compliance from NASDAQ

  
    
  
  
    
      North American Scientific, Inc. (NASDAQ: NASI) today announced that it 
      received a notice from The NASDAQ Stock Market (“NASDAQ”) 
      dated April 4, 2008 indicating that the 180 calendar day compliance 
      period granted to the Company in accordance with Marketplace Rule 
      4450(e)(2) ended on April 2, 2008 and the Company failed to regain 
      compliance with the minimum $1.00 bid price per share requirement for 
      continued listing of its Common Stock on the Nasdaq Capital Market, as 
      set forth in Marketplace Rule 4450(a)(5) (the “Rule). 
      Further, the notice indicated that the Company is not eligible for an 
      additional 180 calendar day compliance period given that it does not 
      meet the Nasdaq Capital Market initial inclusion criteria of $15.0 
      million Market Value of Publicly Held Shares, as set forth in 
      Marketplace Rule 4310(c). Therefore, the Company’s 
      Common Stock is subject to delisting from the Nasdaq Capital Market at 
      the opening of business on April 15, 2008.
    
    
      The Company has until April 11, 2008 to appeal Nasdaq’s 
      determination to delist its common stock to a NASDAQ Listing 
      Qualifications Panel (the “Panel”), 
      which, if granted, will stay the delisting pending the Panel’s 
      decision. The Company plans to file such an appeal by April 11, 2008. If 
      granted a hearing, the Company will be required to provide a plan to 
      regain compliance to the Panel, and, according to the Nasdaq letter, 
      historically Panels have generally viewed a near-term reverse stock 
      split as the only definitive plan acceptable to resolve a bid price 
      deficiency. The Company’s plan will include a 
      one share for five share reverse stock split, approved by its Board of 
      Directors on February 15, 2008, to be voted upon by its Stockholders at 
      its annual meeting to be held on April 29, 2008. However, there can be 
      no assurance the Panel will grant the Company’s 
      request for a hearing or for continued listing.
    
    
      About North American Scientific
    
    
      North American Scientific is a leader in radiation therapy in the fight 
      against cancer. Its innovative products provide physicians with tools 
      for the treatment of various types of cancers. They include Prospera® 
      brachytherapy seeds and SurTRAK™ needles and 
      strands used primarily in the treatment of prostate cancer. In addition 
      the Company plans to commercialize its ClearPath™ 
      multi-channel catheter breast brachytherapy devices in 2007, which are 
      the only devices approved for both high dose and continuous release, or 
      low dose, radiation treatments. The devices are designed to provide 
      flexible, precise dose conformance and an innovative delivery system 
      that is intended to offer the more advanced form of brachytherapy for 
      the treatment of breast cancer. Please visit www.nasmedical.com 
      for more information.
    
    
      Statements included in this release that are not historical facts may 
      be considered forward-looking statements that are subject to a variety 
      of risks and uncertainties. There are a number of important factors that 
      could cause actual results to differ materially from those expressed in 
      any forward-looking statements made by the Company including, but not 
      limited to, the impact of competitive products and pricing, 
      technological changes, changes in relationships with strategic partners 
      and dependence upon strategic partners for the performance of critical 
      activities under collaborative agreements, the ability of the Company to 
      successfully directly market and sell its products, uncertainties 
      relating to patent protection and regulatory approval, the stable supply 
      of appropriate isotopes, research and development estimates, market 
      opportunities, risks associated with strategic opportunities or 
      acquisitions the Company may pursue and the risk factors included in the 
      Company’s filings with the Securities and 
      Exchange Commission. Any forward-looking statements contained in this 
      news release speak only as of the date of this release, and the Company 
      undertakes no obligation to revise or update any forward-looking 
      statements, whether as a result of new information, future results or 
      otherwise.